GlassScriptPhysician profile
Michael D Dubriwny
NPI 1659341808
$8,325.24
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2020: $1,032 · 2021: $2,062 · 2022: $1,703 · 2023: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Education: $64.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.23 |
| Education | $64.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,344.39 | 2019-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $887.70 | 2019-2023 | Rexulti |
| Abbvie INC. | $814.15 | 2021-2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $768.92 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $651.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $598.06 | 2019-2023 | Spravato |
| Alkermes, INC. | $517.31 | 2019-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $484.31 | 2019-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $399.00 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $274.11 | 2019-2023 | Austedo, Austedo Xr |
| Allergan, INC. | $237.95 | 2019-2020 | |
| Axsome Therapeutics, INC. | $224.54 | 2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $217.52 | 2019-2022 | |
| Eisai INC. | $182.11 | 2020-2021 | |
| Shire North American Group INC | $120.68 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $114.41 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $80.31 | 2022-2023 | Qelbree |
| Almatica Pharma LLC | $65.91 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $54.88 | 2019-2021 | |
| Orexo US, INC. | $46.19 | 2022-2023 | Zubsolv |
| Corium, LLC | $33.56 | 2021-2022 | |
| Noven Therapeutics, LLC | $32.25 | 2023 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $32.04 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $31.96 | 2020 | |
| Indivior INC. | $26.10 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $18.60 | 2022 | |
| Biogen, INC. | $14.81 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.89 | 2019 | |
| Bausch Health US, LLC | $13.86 | 2019 | |
| Alfasigma USA, INC. | $12.76 | 2020 | |
| Endo Pharmaceuticals INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dubriwny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.